Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RM-1995 photoimmunotherapy with or without pembrolizumab for solid tumors with liver metastases
jRCT2031220721Phase 1Suspended
- Sponsor
- Rakuten Medical, Inc.
- Start
- Jun 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of RM-1995 and pembrolizumab in Nonhematologic neoplasms (3 arms), sponsored by Rakuten Medical, Inc. Primary endpoints: Onset of dose-limiting toxicity, Adverse events and 1 more. Started Jun 2023; status: suspended.
02
Drugs
RM-1995pembrolizumab
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2031220721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220721.